NeuroOne® to Present its Disruptive Next-Generation Diagnostic Electrode Technology at the NobleCon18 Investor Conference on April 20, 2022
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will present at NobleCon18 from April 19-21, 2022. CEO Dave Rosa will discuss advancements in minimally invasive technologies aimed at treating neurological disorders such as epilepsy and Parkinson's disease. The presentation is scheduled for April 21 at 11:30 a.m. ET, with breakout sessions on April 20 and 21. The event will take place at the Hard Rock Hotel & Casino in Hollywood, Florida. The company is also exploring applications of its technology in artificial intelligence.
- None.
- None.
EDEN PRAIRIE, Minn., April 18, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will present at NobleCon18, Noble Capital Markets' 18th Annual Investor Conference being held April 19-21, 2022.
NobleCon18 Conference | |
Presentation date and time: | Thursday, April 21, 2022; 11:30 a.m. ET |
Breakout sessions: | Wednesday, April 20 at 1:45 p.m.; Thursday, April 21 at 1:00 p.m. |
Location: | Hard Rock Hotel & Casino, Hollywood, Florida |
Registration: | Visit the conference website |
Available beginning April 22 for 90 days |
NeuroOne Chief Executive Officer Dave Rosa will discuss the Company's focus on the development and commercialization of minimally invasive and high-definition/high-precision solutions for epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. These solutions include electrodes that have the potential to reduce the number of hospitalizations and surgical procedures, and reduce costs, while improving patient outcomes due to their potential for offering combination diagnostic and therapeutic functions such as EEG recording and tissue ablation and/or chronic stimulation.
About NeuroOne® Medical Technologies Corporation
NeuroOne is a medical technology company focused on the development and commercialization of minimally invasive and high-definition/high-precision solutions for epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. A combination recording and RF ablation technology is currently under development. In addition, NeuroOne is currently testing its electrodes for long term stimulation. The Company is also investigating the potential application of its technology for artificial intelligence and machine learning. Visit n1mtc.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding potential of our technology to reduce the number of hospitalizations, surgical procedures and reduce costs. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our technology will not perform as expected based on results of our pre-clinical testing; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; risks that we may not have accurately estimated the size and growth potential of the markets for our technology; and other risks and uncertainties related to market and other conditions, the impact of general economic, industry or political conditions in the United States or internationally and those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of the press release and the Company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-its-disruptive-next-generation-diagnostic-electrode-technology-at-the-noblecon18-investor-conference-on-april-20-2022-301526824.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
When will NeuroOne present at NobleCon18?
What is the focus of NeuroOne's presentation at NobleCon18?
Where is the NobleCon18 conference being held?
What are the breakout session times for NeuroOne at NobleCon18?
What is NeuroOne's stock symbol?
